Overview of FTY720 clinical pharmacokinetics and pharmacology.
about
Development of oral immunomodulatory agents in the management of multiple sclerosisPreclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-MitoxyFingolimod for relapsing multiple sclerosis: an update.Fingolimod (FTY720): First approved oral therapy for multiple sclerosisRole of sphingolipids in murine radiation-induced lung injury: protection by sphingosine 1-phosphate analogs.Coxsackievirus-induced myocarditis: new trends in treatment.The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjectsSphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.FTY720 (fingolimod) for relapsing multiple sclerosis.Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies.Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.Severe murine limb-girdle muscular dystrophy type 2C pathology is diminished by FTY720 treatment.Population pharmacokinetics of fingolimod phosphate in healthy participants.Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.New immunosuppresor strategies in the treatment of murine lupus nephritis.Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease
P2860
Q28388704-A605BED1-B582-4F34-B6A4-9F99DB77A328Q28553993-A242D2D4-025E-41E8-AB3A-62F6DF2774AFQ34618474-44FCA129-2F44-4565-8DC9-1FB0F667FBE9Q35052362-86976244-5732-4F5C-AEC4-37972728D044Q35225101-22CABA9D-24A6-436D-BA6C-366E2ED7C0AEQ36233532-EC871A81-D4E2-427D-9BC7-7D560D0FA955Q36803411-1616077D-FCAE-4E46-A8F3-D806BE5538E8Q37056490-CD8C106E-4C79-4D95-AFA3-B41E46E2AB77Q37154788-DDC74292-FD13-4C22-BFAA-33CEFA93EBC7Q37193113-7A21527E-886E-4FD8-94DF-4C1DB9B53A38Q37382152-9A9D2FFD-6B8C-44B9-9BD4-98D4BA1356B6Q37397209-F904CE42-0BF4-4A03-BBA3-4A525C56A1A7Q37890469-B3DA1F24-2AC6-4693-9680-FCDD95116AB3Q37905767-E39B687C-ABCE-4CAC-9437-FBF13EE8845EQ39771285-D6661058-69B8-48F7-9A0F-50D090735B4BQ41019141-55FBAB93-BC88-41E8-80D0-2A762E8871C7Q45171971-F54C14A5-167F-4D7A-BFBB-4CC4BB373B1FQ46178229-387EF8C5-6A15-4374-9DA8-AC7DA6A10FBDQ46908020-58CBFE3A-3627-4B61-A9DB-9690FB635994Q51767729-8BCEFDDA-7863-4D21-8FC2-8BA4A8592E52Q58775998-FD94E872-8158-4A86-AAF7-DFC8B17604F8
P2860
Overview of FTY720 clinical pharmacokinetics and pharmacology.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@ast
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@en
type
label
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@ast
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@en
prefLabel
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@ast
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@en
P2093
P1476
Overview of FTY720 clinical pharmacokinetics and pharmacology.
@en
P2093
Alan J Slade
John M Kovarik
Robert L Schmouder
P304
P356
10.1097/00007691-200412000-00001
P577
2004-12-01T00:00:00Z